On June 20, 2026, India’s food regulator, FSSAI, revised its food additive rules to prohibit the use of high-purity hyaluronic acid (≥95%) in nutritional supplements and complementary foods for infants and young children aged 0–36 months. The measure takes effect immediately, while previously approved formulations must complete label and formula filing updates within 90 days. For ingredient suppliers, infant nutrition manufacturers, regulatory teams, and cross-border market participants, the update deserves close attention because it affects both product compliance and the timing of market adjustments.

What the amendment formally changes

According to the information provided, FSSAI issued amendment notice No.FSSAI/REG/2026/88 on June 20, 2026. The notice states that high-purity hyaluronic acid with a purity level of 95% or above is not permitted in nutritional supplements and complementary foods intended for children aged 0–36 months. The restriction applies from the date of issuance. For formulations that had already been approved before this change, label updates and formula filing revisions must be completed within 90 days.

Where the immediate business impact may appear

Infant nutrition product developers face direct formula review pressure

From an industry perspective, the most direct impact falls on companies developing or marketing infant nutritional supplements and complementary foods for the 0–36 month segment. If any relevant product uses high-purity hyaluronic acid at the specified threshold, the effect is likely to appear first in formula assessment, product documentation, and compliance review. What deserves closer attention is whether existing stock-keeping units, application files, and product claims remain aligned with the revised rule.

Ingredient procurement and supplier coordination may need adjustment

Analysis shows that procurement teams and ingredient suppliers connected to infant-category products may need to recheck material specifications, downstream use scenarios, and customer communication. The key issue is not simply the ingredient itself, but whether the material is being supplied into products covered by the 0–36 month scope and whether its purity level reaches the threshold named in the amendment. This can affect order planning, specification confirmation, and supporting compliance documents.

Regulatory and filing functions will need to work against the 90-day window

For businesses with previously approved formulations, the 90-day requirement creates a defined operational timeline. Observably, regulatory affairs, labeling, and market access teams may need to coordinate more closely on filing changes, packaging updates, and internal review sequences. The practical impact is likely to be concentrated in documentation workflows rather than in broader category rules beyond the scope stated in the notice.

What companies should watch now

Track the exact product scope in use

Companies should first distinguish whether their products fall within nutritional supplements and complementary foods for children aged 0–36 months, because that is the scope explicitly covered by the provided information. In practice, this affects how teams prioritize product screening and internal compliance checks.

Separate immediate compliance tasks from broader strategy discussions

Analysis shows that the immediate requirement is clear: the ban applies at once, and previously approved formulas have a 90-day period for label and filing updates. What deserves closer attention is the difference between mandatory short-term actions and any broader commercial interpretation that companies may be tempted to make before further official clarification appears.

Review supplier files and customer-facing materials

For companies involved in supply or contract manufacturing, it is prudent to verify raw material specifications, formula records, labels, and filing materials that reference high-purity hyaluronic acid. Customer communication may also need to be aligned with the revised rule, especially where existing approvals or ongoing deliveries are involved.

Prepare for follow-up clarification and implementation questions

Observably, implementation often depends not only on the headline rule but also on how businesses interpret scope, timing, and documentation requirements in day-to-day operations. Companies should therefore keep records organized and be ready to adjust internal processes if additional official wording or interpretive guidance emerges.

How this signal is best understood at this stage

Analysis shows that this is already a concrete compliance change for the affected product segment, not merely a policy discussion. At the same time, it is more appropriate to understand it as a targeted regulatory action within a defined application area rather than as a confirmed shift covering all uses of hyaluronic acid in food-related products. The industry still needs to watch how businesses implement the rule in filings, labels, and supply arrangements over the coming weeks.

Why the update matters beyond the headline

This development matters because it combines immediate effect with a short transition requirement for products already approved, making it both a regulatory event and an operational deadline. From an industry perspective, the update is best understood as a near-term compliance trigger for infant nutrition stakeholders and a longer-term signal that ingredient eligibility in sensitive age-group products remains under close scrutiny. For now, a measured reading is more appropriate than broad conclusions.

Basis of this article and ongoing verification

This article is based on the user-provided news title, event date, and event summary concerning FSSAI amendment notice No.FSSAI/REG/2026/88 issued on June 20, 2026. For this type of industry update, source categories typically worth checking include official regulatory notices, company disclosures, industry association updates, authoritative media coverage, and standards-related documents. A specific official source link was not provided in the input, so continued verification remains necessary. If further updates appear, the main areas to watch are official wording, implementation practice, and any follow-on clarification affecting labeling or formula filing procedures.